查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1987163

失智症治療藥物的市場規模、佔有率、趨勢和預測：按適應症、藥物類別、分銷管道和地區分類，2026-2034 年

Dementia Drugs Market Size, Share, Trends and Forecast by Indication, Drug Class, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2025年全球失智症治療市場規模為209.8億美元。展望未來，IMARC Group預測，該市場將以6.6%的複合年成長率從2026年成長至2034年，到2034年達到373.7億美元。目前，北美市場主導地位，預計2025年將佔32%的市場。該地區擁有完善的醫療基礎設施、較高的診斷意識、對藥物研發的大量投入以及可靠的支付機制，這些因素促進了成熟療法和創新治療方法的應用，並推動了失智症治療方法市場佔有率的成長。

全球人口快速老化，以及阿茲海默症和血管性失智症等神經退化性疾病盛行率的顯著上升，是全球失智症治療市場的主要驅動力。隨著人們對早期診斷和及時介入的認知不斷提高，越來越多的人尋求治療，患者群體也不斷擴大。此外，政府和機構對失智症研究投入的增加，正在加速創新療法的發現，例如針對疾病潛在機製而非僅僅治療症狀的疾病緩解疾病藥物。從單純的症狀治療轉向生物製藥和單株抗體，正在改變治療方式，並推動失智症治療市場的成長。此外，已開發國家和開發中國家醫療保健支出的增加，以及神經系統疾病保險覆蓋範圍的擴大，使得患者更容易獲得尖端的失智症治療，進一步促進了全球市場的穩定成長。

美國之所以發展成為失智症治療領域的龐大市場，原因有以下幾點：其強大的研究基礎設施、完善的醫療保健體係以及積極的法規環境，促進了尖端失智症療法的快速商業化。政府致力於提高公眾對失智症的認知，並資助專門的研究項目，這些舉措也為國內產業的發展提供了支持。例如，阿茲海默症協會估計，到2025年，美國將有720萬65歲及以上的老年人患有阿茲海默症，這凸顯了需要治療性介入的龐大且不斷成長的人群。神經影像學和基於生物標記的評估等先進診斷技術的普及，有助於早期發現和啟動治療。此外，聯邦醫療保險（Medicare）和核准的失智症治療保險體系確保了患者的廣泛可及性，使美國在失智症治療市場中佔據了舉足輕重的地位。

失智症治療市場的發展趨勢：

擴大疾病修正治療的應用

隨著緩解疾病療法（即著眼於神經退化性疾病的潛在發病機製而非僅僅治療症狀的療法）的日益普及，失智症治療市場正經歷著革命性的變革。旨在減少大腦中BETA-澱粉樣蛋白斑塊的抗澱粉樣蛋白單株抗體，隨著越來越多的臨床數據支持其療效，正受到神經科和醫療保健專業人員的青睞。這些前沿生物製藥代表著與傳統症狀治療的模式轉移，因為它們有可能阻止認知衰退，並維持早期患者的功能獨立性。例如，如果美國食品藥物管理局(FDA) 在 2025 年 1 月核准LEQEMBI（lecanemab）靜脈維持治療的補充生技藥品核准申請 (sBLA)，那麼已完成第一階段治療的患者將能夠轉為每月一次的輸注方案。不斷擴充的抗Tau蛋白療法和聯合治療研發管線進一步拓展了失智症治療的選擇。

全球人口老化正在推動需求成長。

神經系統疾病的盛行率老齡化成長而急劇上升，全球老化成為推動失智症治療需求的主要因素。在已開發國家和開發中國家，預期壽命延長和出生率下降等人口結構變化導致人口老化，進而導致需要失智症治療的患者人數增加。各國政府和醫療機構正在製定國家政策以應對日益嚴重的失智症問題。此外，人們對失智症的徵兆和症狀的認知不斷提高，促使更多人尋求醫療協助，從而增加了接受失智症治療的患者人數。新興經濟體醫療基礎設施的改善擴大了神經系統疾病醫療服務的覆蓋範圍，進一步刺激了對失智症藥物的需求。這種由人口結構變化驅動的需求促使醫療系統加強神經系統疾病的診療能力，並鼓勵製藥公司投資研發新的治療方法，從而支持全球全部區域失智症治療市場預計的持續成長。

數位診斷技術與個人化醫療的進步

先進的數位診斷技術與個人化醫療方法的結合，顯著提升了失智症的早期檢測和個人化治療水準。基於生物標記的診斷方法，例如血液檢測、腦脊髓液分析和澱粉樣蛋白正子斷層掃描（PET），能夠幫助醫生在疾病的早期階段識別其發病機制，從而在治療性介入最為有效的時候進行干預。這種早期診斷能力使得更多患者能夠接受治療，進而增加了對已通過核准的失智症藥物的需求。此外，神經影像學結果和認知功能評估數據正被應用於人工智慧和機器學習演算法的分析，以支援更精準的臨床決策，並為每位患者選擇最合適的治療方法。隨著遠端醫療平台和遠距認知監測工具的普及，患者獲得專業神經科護理的機會進一步增加，尤其是在貧困和農村地區。同時，製藥公司正日益利用數位健康數據和真實世界數據（REW）來改進治療通訊協定，並開發能夠根據特定患者特徵匹配最佳治療方案的伴隨診斷，從而推動失智症藥物市場的擴張。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球失智症治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依應用領域分類

  • 路易氏體失智症
  • 帕金森氏症和失智症
  • 阿茲海默症
  • 血管性失智症
  • 其他

第7章 市場區隔：依藥物類別分類

  • 膽鹼酯酶抑制劑
  • NMDA拮抗劑及其組合藥物

第8章 市場區隔：依分銷通路分類

  • 零售藥房
  • 醫院藥房
  • 網路藥房

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：促進因素、阻礙因素和機遇

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbvie Inc.
    • Apotex Inc.
    • Biogen Inc.
    • Eisai Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc.
Product Code: SR112026A7490

The global dementia drugs market size was valued at USD 20.98 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 37.37 Billion by 2034, exhibiting a CAGR of 6.6% from 2026-2034. North America currently dominates the market, holding a market share of 32% in 2025. The region benefits from advanced healthcare infrastructure, high diagnostic awareness, large investments in pharmaceutical R&D, and reliable payment mechanisms that facilitate the widespread adoption of both established and novel dementia treatments, all contributing to the dementia drugs market share.

The world's rapidly aging population, which has resulted in a substantial increase in the prevalence of neurodegenerative disorders like Alzheimer's disease and vascular dementia, is the primary driver of the global market for dementia drugs. As more people seek therapy as a result of greater awareness of early diagnosis and timely action, the pool of addressable patients is expanding. Additionally, increased government and institutional funding for dementia research is accelerating the discovery of innovative therapeutic agents, such as disease-modifying drugs that target underlying disease mechanisms rather than just treating symptoms. The shift from purely symptomatic treatments toward biologic agents and monoclonal antibodies is reshaping the treatment landscape, supporting the dementia drugs market growth. Furthermore, rising healthcare spending in both developed and developing nations, along with increased insurance coverage for neurological disorders, is improving patient access to cutting-edge dementia treatments and encouraging steady global market growth.

The US has grown into a sizable market for dementia drugs for a number of reasons. The rapid commercialization of cutting-edge dementia medicines is facilitated by the country's strong research infrastructure, established healthcare system, and proactive regulatory environment. Government initiatives to increase dementia awareness and finance specialist research programs are also helping the home industry. The Alzheimer's Association, for example, estimates that 7.2 million Americans 65 and older will have Alzheimer's disease in 2025, highlighting the sizeable and expanding patient population in need of therapeutic intervention. Early detection and treatment initiation are supported by the availability of sophisticated diagnostic techniques, such as neuroimaging technology and biomarker-based evaluations. Furthermore, Medicare coverage for authorized dementia treatments and strong insurance frameworks guarantee widespread patient access, positioning the United States as a key contributor to the dementia drugs market outlook.

DEMENTIA DRUGS MARKET TRENDS:

Rising Adoption of Disease-Modifying Therapies

With the growing use of disease-modifying treatments that focus on the underlying pathogenic mechanisms of neurodegenerative disorders rather than just treating their symptoms, the market for dementia medications is undergoing a revolutionary change. With more and more clinical data proving its effectiveness, anti-amyloid monoclonal antibodies, which are intended to lessen amyloid-beta plaques in the brain, are becoming increasingly popular among neurologists and medical professionals. These cutting-edge biologics provide the potential to arrest cognitive decline and maintain functional independence in individuals with early-stage illness, marking a paradigm shift from traditional symptomatic therapies. For example, patients who finished the first phase of treatment could switch to a once-monthly infusion schedule once the U.S. FDA approved the Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab) intravenous maintenance dosage in January 2025. The growing pipeline of anti-tau and combination therapies further reinforces the expanding therapeutic arsenal available for dementia management.

Expanding Global Aging Population Driving Demand

Given that the prevalence of neurological illnesses rises sharply with age, the world's aging population is also a major factor driving up demand for dementia treatments. In both industrialized and developing nations, the population is aging due to demographic shifts like as longer life expectancies and lower birth rates, which increases the need for dementia treatment patients. In order to address the growing prevalence of dementia, governments and healthcare organizations are also developing national policies. Additionally, as more people become aware of the signs and symptoms of dementia, more people are consulting with doctors, which expands the number of people receiving dementia therapy. The demand for dementia drugs is being supported by the expansion of access to neurological healthcare services brought about by the development of healthcare infrastructure in emerging nations. This demographic-driven demand is pushing healthcare systems to improve their neurological care capacities and pharmaceutical companies to invest in the development of new treatments, supporting sustained dementia drugs market forecast expansion across all major regions globally.

Advancing Digital Diagnostics and Personalized Treatment

The combination of advanced digital diagnostic technologies and customized medicine approaches is significantly improving the early identification and individualized treatment of dementia. Biomarker-based diagnostic methods, including as blood-based assays, cerebrospinal fluid analysis, and amyloid positron emission tomography scans, are assisting doctors in identifying disease pathology early on, when therapeutic interventions are most effective. Because of these earlier diagnostic capabilities, more people are able to receive treatment, which in turn is driving up demand for approved dementia medications. Additionally, neuroimaging results and cognitive assessment data are being evaluated using artificial intelligence and machine learning algorithms to support more precise clinical decision-making and the optimal therapy option for each patient. Access to specialized neurology consultations is being further improved by the expanding use of telemedicine platforms and remote cognitive monitoring tools, especially for patients in impoverished and rural locations. Additionally, pharmaceutical firms are using digital health data and real-world evidence more and more to improve treatment protocols and create companion diagnostics that match particular patient profiles with the best treatment plans, thereby contributing to the expanding dementia drugs market trends.

DEMENTIA DRUGS INDUSTRY SEGMENTATION:

Analysis by Indication:

  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer's Disease
  • Vascular Dementia
  • Others

Alzheimer's disease holds 48% of the market share. Alzheimer's disease, recognized as the most prevalent form of dementia globally, represents the primary therapeutic focus within the dementia drugs landscape. The condition is characterized by progressive cognitive decline, memory impairment, and loss of functional independence, necessitating long-term pharmacological management. The dominant position of this segment is attributed to the high prevalence of Alzheimer's among elderly populations, strong clinical awareness, and the availability of multiple approved treatment options including cholinesterase inhibitors and NMDA receptor antagonists. For example, the World Health Organization reports that between 60 and 70 percent of dementia cases worldwide are caused by Alzheimer's disease, demonstrating the disease's extreme frequency among neurodegenerative diseases. Furthermore, the recent approval and commercialization of disease-modifying anti-amyloid therapies specifically targeting Alzheimer's pathology are generating substantial new revenue streams and reinforcing the segment's leading market position.

Analysis by Drug Class:

  • Cholinesterase Inhibitors
  • NMDA Antagonists and its Combination Drugs

Cholinesterase inhibitors lead the market with a share of 45%. Cholinesterase inhibitors are the most widely used class of drugs in the dementia drugs market, acting through the inhibition of acetylcholine breakdown by preventing the action of acetylcholinesterase, an enzyme responsible for the degradation of acetylcholine, a neurotransmitter that plays a pivotal role in memory and cognitive functions. The widespread use of cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, in the treatment of mild to moderate dementia has made this class of drugs the gold standard in dementia pharmacotherapy. The widespread use of these drugs in generic forms ensures widespread accessibility and affordability, further enhancing market penetration in both developed and developing countries. Moreover, the adaptability of these drugs in the treatment of various forms of dementia, including Alzheimer's disease and Lewy body dementia, has further contributed to the sustained use of these drugs. Ongoing research continues to validate the long-term cognitive and functional benefits associated with cholinesterase inhibitor therapy, further enhancing physician confidence in the use of these drugs as first-line pharmacologic agents. Moreover, the development of novel drug delivery systems, including transdermal patches and extended-release oral preparations, is further enhancing patient compliance and utilization.

Analysis by Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Retail pharmacies dominate the market, with a share of 50%. Retail pharmacies are the main distribution channel for dementia medications, providing patients with convenient access to chronic disease management therapies via community-based retail pharmacy outlets. The pre-eminence of this sector is a result of the chronic nature of dementia therapy, which necessitates ongoing prescription refills that are best managed via accessible retail pharmacy networks. Most dementia medications, especially oral cholinesterase inhibitors and NMDA receptor antagonists, are prescribed as ongoing outpatient therapies, making retail pharmacies the logical point of access for patients and families. In addition, the development of pharmacy benefit management programs and insurance coverage structures continues to facilitate the use of retail pharmacies for the dispensing of dementia medications. The increasing alignment of pharmacist-provided medication management services, such as medication adherence and therapeutic monitoring, is further enhancing the role of retail pharmacies in dementia care. Moreover, the development of chain pharmacy networks and their strategic location ensures widespread availability of critical dementia medications.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 32% of the share, enjoys the leading position in the market. The dominance of this region is largely fueled by its well-developed healthcare infrastructure, large number of Alzheimer's and dementia patients in the aging population, and a progressive regulatory framework that encourages the swift approval and launch of promising new dementia treatments. The United States, being the largest country market in this region, is aided by significant government investments in neurological research, robust insurance coverage structures, and widespread acceptance of both traditional and new treatment modalities. Moreover, the presence of proactive national dementia plans, sophisticated diagnostic facilities, and successful pharmaceutical companies further cements the leading market status of North America. The growing accessibility of biomarker screening facilities and memory care centers is helping to promote earlier diagnosis and treatment in the region. In addition, public-private partnerships between academic medical institutions and pharmaceutical firms are helping to accelerate clinical trials and facilitate the swift translation of research advances into new commercialized treatment modalities.

KEY REGIONAL TAKEAWAYS:

United States Dementia Drugs Market Analysis

Due to its huge healthcare system, high illness prevalence, and strong pharmaceutical innovation ecosystem, the United States is the world's largest national market for dementia medications. The aged population is now significantly more vulnerable to Alzheimer's disease and other dementias due to the aging baby boomer generation, which has resulted in a persistent need for both symptomatic and disease-modifying treatments. Dementia research continues to get substantial support from federal organizations, such as the National Institutes of Health and the National Institute on Aging, which makes it easier to create and test new treatment options. Promising dementia therapies can enter the market more quickly thanks to the regulatory structure run by the U.S. Food and Drug Administration, which includes accelerated approval and breakthrough therapy designation procedures. Expanding Medicare and commercial insurance coverage guarantees widespread patient access to approved drugs, and growing use of biomarker-based diagnostic techniques is facilitating earlier disease identification and treatment commencement. Comprehensive patient evaluation and customized treatment planning are supported by the nation's extensive network of world-class academic medical centers and specialized memory care clinics. Furthermore, increasing public health initiatives aimed at raising awareness of dementia are promoting prompt medical consultations among vulnerable groups, which increases the number of patients who may be served and sustains the need for pharmaceuticals.

Europe Dementia Drugs Market Analysis

Due to its advanced healthcare systems, aging population, and increasing focus on managing neurological diseases throughout its main countries, Europe is a prominent market for dementia medications. The frequency of dementia is rising in countries like Germany, the UK, France, Italy, and Spain as a result of longer life expectancies and growing numbers of senior people. The region's national health systems are gradually increasing their coverage of dementia diagnosis and treatment, giving patients better access to both tried-and-true and cutting-edge treatment options. In order to guarantee that patients receive the most recent pharmacological developments, the European Medicines Agency's regulatory framework makes it easier for member states to evaluate and approve novel treatments. The development of next-generation dementia medicines and diagnostic tools is also being accelerated by cooperative research projects supported by European Union programs, which is bolstering the therapeutic landscape in the area. The region's increasing investment in multidisciplinary neurology centers and specialist dementia care facilities is improving patient care and promoting more all-encompassing treatment strategies. Additionally, the clinical understanding of neurodegenerative diseases is being advanced and knowledge exchanged by European research institutions through increased cross-border cooperation.

Asia-Pacific Dementia Drugs Market Analysis

Due to increasingly aging populations, rising disease prevalence, and improving healthcare infrastructure throughout major nations, the Asia-Pacific area is becoming one of the fastest-growing markets for dementia medications. The burden of neurodegenerative diseases is rising as a result of major population shifts in nations like China, Japan, India, South Korea, and Australia. To combat this escalating issue, governments throughout the area are boosting healthcare spending and putting national dementia programs into action. For instance, according to Eisai, approximately 17 million people in China were living with mild cognitive impairment or mild dementia caused by Alzheimer's disease in 2024, a number expected to rise substantially as the population ages. The Asia-Pacific area is positioned for continued market expansion due to the increasing availability of both patented and generic dementia medications, as well as enhanced diagnostic capabilities and increased clinical trial activity.

Latin America Dementia Drugs Market Analysis

Due to regional improvements in healthcare access, aging populations, and increased awareness of neurodegenerative disorders, the market for dementia drugs is progressively expanding in Latin America. In countries like Brazil and Mexico, where the population is getting older, dementia is becoming more common and treatment approaches are becoming more necessary. International pharmaceutical companies are expanding their market presence in the region to address the growing unmet therapeutic demands, and government healthcare systems are progressively including neurological care into their offerings. Additionally, growing healthcare literacy and urbanization are facilitating greater patient engagement with formal medical systems, leading to faster dementia diagnosis and treatment for a variety of socioeconomic groups.

Middle East and Africa Dementia Drugs Market Analysis

The market for dementia medications is progressively expanding in the Middle East and Africa due to factors such growing senior populations in major economies, better healthcare infrastructure, and growing awareness of neurodegenerative diseases. Although the area now has a comparatively lesser portion of the worldwide market, urbanization and demographic shifts are driving up the prevalence of dementia and increasing the demand for therapeutic solutions. The region's market is anticipated to rise as a result of healthcare modernization programs, rising pharmaceutical distribution networks, and increased government focus on managing chronic diseases. Furthermore, knowledge transfer and local capacity for dementia diagnosis and treatment delivery are being strengthened by growing collaborations between international organizations and regional healthcare authorities.

COMPETITIVE LANDSCAPE:

The coexistence of established pharmaceutical corporations and biotechnology companies with a focus on distinct techniques represents the competitive landscape in the dementia drug market. Leading businesses are actively working on research and development projects to improve their neurology products, with a focus on disease-modifying treatments that target the tau and amyloid-beta proteins. New chemicals are being developed more quickly because to partnerships between pharmaceutical corporations and academic institutions. Prominent businesses are developing biologics internally and partnering with others to commercialize them. To make therapy more convenient for patients, companies are also developing new medication delivery methods, such as transdermal and subcutaneous patches, and combination medicines. By creating more reasonably priced copies of the current cholinesterase inhibitors and NMDA receptor antagonists, generic businesses are also helping to open up the market. Furthermore, businesses are utilizing companion diagnostics and precision medicine's capabilities more and more to differentiate their goods and enhance their market standing in the competitive dementia treatment industry.

The report provides a comprehensive analysis of the competitive landscape in the dementia drugs market with detailed profiles of all major companies, including:

  • Abbvie Inc.
  • Apotex Inc.
  • Biogen Inc.
  • Eisai Co. Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the dementia drugs market?

2. What is the future outlook of dementia drugs market?

3. What are the key factors driving the dementia drugs market?

4. Which region accounts for the largest dementia drugs market share?

5. Which are the leading companies in the global dementia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Dementia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Lewy Body Dementia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parkinson's Disease Dementia
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alzheimer's Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vascular Dementia
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Cholinesterase Inhibitors
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 NMDA Antagonists and its Combination Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Retail Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hospital Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Apotex Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Biogen Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Dementia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Dementia Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Dementia Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Dementia Drugs Market: Breakup by Indication (in %), 2025
  • Figure 5: Global: Dementia Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 6: Global: Dementia Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Dementia Drugs Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Dementia Drugs (Lewy Body Dementia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Dementia Drugs (Lewy Body Dementia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Dementia Drugs (Parkinson's Disease Dementia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Dementia Drugs (Parkinson's Disease Dementia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Dementia Drugs (Alzheimer's Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Dementia Drugs (Alzheimer's Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Dementia Drugs (Vascular Dementia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Dementia Drugs (Vascular Dementia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Dementia Drugs (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Dementia Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Dementia Drugs (Cholinesterase Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Dementia Drugs (Cholinesterase Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Dementia Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Dementia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Dementia Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Dementia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Dementia Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Dementia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: North America: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: North America: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: United States: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: United States: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Canada: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Canada: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Asia-Pacific: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Asia-Pacific: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: China: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: China: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Japan: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Japan: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: India: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: India: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: South Korea: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: South Korea: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Australia: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Australia: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Indonesia: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Indonesia: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Others: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Others: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Germany: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Germany: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: France: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: France: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United Kingdom: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United Kingdom: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Italy: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Italy: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Spain: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Spain: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Russia: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Russia: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Brazil: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Brazil: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Mexico: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Mexico: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Middle East and Africa: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Middle East and Africa: Dementia Drugs Market: Breakup by Country (in %), 2025
  • Figure 76: Middle East and Africa: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Dementia Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Dementia Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Dementia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Dementia Drugs Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Dementia Drugs Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 3: Global: Dementia Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 4: Global: Dementia Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Dementia Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Dementia Drugs Market: Competitive Structure
  • Table 7: Global: Dementia Drugs Market: Key Players